Correction to: Afatinib for the treatment of non-small cell lung cancer
Following publication, an error was noted in the manuscript ‘Afatinib for the treatment of non-small cell lung cancer’ by Biello F et al. (Expert Opin Orphan Drugs, Vol 3, Issue 11, 2015, DOI: 10.1517/21678707.2015.1092379).
The abstract states ‘the pooled analysis of LUX-Lung 3 and 6 data in patients harbouring Del19 is the only demonstration of a statistical improvement in overall survival with afatinib.’ This is incorrect – the pooled analysis showed a statistical benefit in overall survival of all common mutations, with each trial independent of each other showing a statistical overall survival benefit in the deletion 19 subgroups. The abstract has been corrected to read ‘the pooled analysis of LUX-Lung 3 and 6 data showed a statistical benefit in overall survival of all common mutations.’
In addition, in the Expert Opinion section of the main text the following sentence ‘The conclusion for now is that relevant differences among afatinib, gefitinib and erlotinib have not emerged so far, as they all induce an important improvement in PFS[30], but it could be useful to note that the fusion of LUX-Lung 3 and 6 data in patients harboring Del19 demonstrate a statistically improvement in OS and that afatinib could be efficient in some EGFR uncommon mutations.’ has been changed to read ‘The conclusion for now is that relevant differences among afatinib, gefitinib and erlotinib have not emerged so far, as they all induce an important improvement in PFS[30], but it could be useful to note that the fusion of LUX-Lung 3 and 6 data in patients harboring EGFR common mutations demonstrate a statistical improvement in OS and that afatinib could be efficient in some EGFR uncommon mutations.’